Add this topic to your myFT Digest for news straight to your inbox
Gilead’s potential coronavirus treatment stirs investor hopes but evidence on effectiveness is mixed
Remdesivir news moves markets more than economic data or Fed action
US-run trial of Gilead coronavirus therapy demonstrates ‘significant positive effect’
Key measure of American business investment fell only marginally last month
Exclusive: Disappointing results revealed in draft documents published accidentally by WHO
The whipsawing after economies locked down begins again as hopes rise of cities reopening
US shares rise after leaked report enthused about benefits of remdesivir in 125 Covid-19 patients
Early impressions from US study show severely ill patients in clinical trial recovering quickly
Antiviral treatment helps two-thirds of patients in New England Journal of Medicine study
Study argues prices for potential treatments are far higher than the actual cost of production
Drugmaker had come under fire for ‘orphan’ ranking that conferred pricing and tax benefits
Activists slam US drugmaker for seeking exclusivity ‘despite calls for solidarity’ to tackle pandemic
Welcome to Due Diligence, the FT’s daily deals briefing
US drugmaker becomes the latest to try to push into cancer treatments
Developing new treatments is costly. Regulators’ expectations are high, as are those of investors
Netflix, Clorox and drugmakers weather market rout sparked by coronavirus
Lawsuit claims drugmaker reaped billions of dollars through taxpayer-funded research
Move comes amid increasing scrutiny of drugmaker over pricing practices
Drugmaker could be liable for billions in royalties to US government
Drugmaker’s investment in Galapagos will gain it access to pipeline of drugs
Clinical trials show reduced regimen still effective at controlling virus
Pharmaceuticals chief will replace John Milligan who announced his departure in July
Biotech group says John Mulligan to step down at the end of the year
International Edition